ENTRY       D11055                      Drug
NAME        Fremanezumab (USAN/INN);
            Fremanezumab (genetical recombination) (JAN);
            Fremanezumab-vfrm;
            Ajovy (TN)
PRODUCT     AJOVY (Teva Pharmaceuticals USA)
FORMULA     C6470H9952N1716O2016S46
EXACT_MASS  145415.6128
MOL_WEIGHT  145505.5255
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYWISWVRQA PGKGLEWVAE IRSESDASAT
            HYAEAVKGRF TISRDNAKNS LYLQMNSLRA EDTAVYYCLA YFDYGLAIQN YWGQGTLVTV
            SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
            SSGLYSLSSV VTVPSSNFGT QTYTCNVDHK PSNTKVDKTV ERKCCVECPP CPAPPVAGPS
            VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVQFNWYV DGVEVHNAKT KPREEQFNST
            FRVVSVLTVV HQDWLNGKEY KCKVSNKGLP SSIEKTISKT KGQPREPQVY TLPPSREEMT
            KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPMLD SDGSFFLYSK LTVDKSRWQQ
            GNVFSCSVMH EALHNHYTQK SLSLSPGK
            (Light chain)
            EIVLTQSPAT LSLSPGERAT LSCKASKRVT TYVSWYQQKP GQAPRLLIYG ASNRYLGIPA
            RFSGSGSGTD FTLTISSLEP EDFAVYYCSQ SYNYPYTFGQ GTKLEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H98, H136-L214, H149-H205, H224-H'224, H225-H'225, H228-H'228, H231-H'231, H262-H322, H368-H426, H'22-H'98, H'136-L'214, H'149-H'205, H'262-H'322, H'368-H'426, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  TYPE      Peptide
REMARK      Therapeutic category: 1190
            ATC code: N02CD03
            Product: D11055<JP/US>
EFFICACY    Antimigraine, Anti-calcitonin gene related peptide (GCRP) antibody
  TYPE      Monoclonal antibody
TARGET      CALCA (CGRP) [HSA:796] [KO:K12332]
  PATHWAY   hsa04080(796)  Neuroactive ligand-receptor interaction
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N02 ANALGESICS
               N02C ANTIMIGRAINE PREPARATIONS
                N02CD Calcitonin gene-related peptide (CGRP) antagonists
                 N02CD03 Fremanezumab
                  D11055  Fremanezumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antimigraine Agents
              Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
               Fremanezumab
                D11055  Fremanezumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              11  Agents affecting central nervous system
               119  Miscellaneous
                1190  Miscellaneous
                 D11055  Fremanezumab (USAN/INN); Fremanezumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Circulatory system
                CALCA (CGRP)
                 D11055  Fremanezumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11055
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11055
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11055
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11055
DBLINKS     CAS: 1655501-53-3
            PubChem: 363669768
///
